HWAM
URGN icon

Hennion & Walsh Asset Management’s UroGen Pharma URGN Stock Holding History

Hennion & Walsh Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
276,696
+93,192
+51% +$2.53M 0.29% 69
2026
Q1 		$3.3M Buy
183,504
+21,580
+13% +$433K 0.11% 239
2025
Q4 		$3.79M Buy
161,924
+96,741
+148% +$2.1M 0.13% 198
2025
Q3 		$1.3M Buy
65,183
+26,828
+70% +$482K 0.05% 451
2025
Q2 		$525K Buy
+38,355
New +$368K 0.02% 656

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Hennion & Walsh Asset Management's URGN Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its UroGen Pharma (URGN) stake by 51% in Q2 2026, buying an estimated $2.53M and bringing the position to 276,696 shares worth $10.2M. The position accounts for 0.29% of the portfolio, ranked #69.

Hennion & Walsh Asset Management first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Hennion & Walsh Asset Management held 276,696 shares of UroGen Pharma worth $10.2M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 93,192 UroGen Pharma shares in Q2 2026, an estimated $2.53M.
  • UroGen Pharma made up 0.29% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #69 holding.
  • Hennion & Walsh Asset Management first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.